A Study to Explore the Efficacy and Safety of HWH486 in Adults With Chronic Spontaneous Urticaria

NCT06295302 | Recruiting Phase 2

• 1 other identifier: RFCU-IIa-202308
• Study Type: interventional
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

This is a multicenter, randomized, double-bind and placebo-controlled phase IIa dose-finding study to assess the safety and efficacy of HWH486 in adults with chronic spontaneous urticaria (CSU). In addition, the pharmacokinetic characteristics will also be investigated.

Conditions

Chronic Spontaneous Urticaria

Outcome Measures

Primary Outcomes (1)

• Change in Urticaria Activity Score (UAS) over a 7-day period (UAS7)

  Weekly Urticaria Activity Score (UAS7; range 0-42; higher scores reflect greater disease activity)

  Baseline, Week 4

Secondary Outcomes (2)

• Change in Hive Severity Score (HSS) over a 7-day period (HSS7)

  Baseline to Week 4

• Change in Itch Severity Score (ISS) over a 7-day period (ISS7)

  Baseline to Week 4

Study Arms (2)

HWH486

EXPERIMENTAL

Drug: HWH486

Placebo

PLACEBO COMPARATOR

Drug: Placebo

Interventions

HWH486 DRUG

HWH486 capsule was administrated orally

HWH486

Placebo DRUG

Matching placebo was administrated orally

Placebo

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18, ≤70 years old;
• Participants with chronic spontaneous urticaria (CSU) at the time of randomization as defined by the following: presence of itch and hives for ≥ 6 consecutive weeks prior to screening, despite second generation H1-antihistamine during this period; Urticaria Activity Score (UAS7) (range 0-42) ≥16, Hives Severity Score (HSS7) (range 0-21) ≥ 6 and Itch Severity Score (ISS7) (range 0-21) ≥ 6 during 7 consecutive days prior to randomization; CSU duration ≥6 months prior to screening (defined as the onset of CSU as determined by the investigator based on all available supporting documentation).
• Willing and able to complete the Urticaria Participant Daily eDiary (UPDD) for the duration of the study;
• Willing to take background medication and emergency medication according to the study protocol.
• \) Written informed consent signed voluntarily by the patient or their legal representatives.

You may not qualify if:

• Previous use of HWH486 or other Bruton's tyrosine kinase(BTK) inhibitors;
• Participants having a predominant or sole trigger of their chronic urticaria (chronic inducible urticaria);
• Any other skin disease associated with chronic itching that might influence in the investigator's opinion the study evaluations and results, e.g. atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis
• With symptoms or signs of progressive or uncontrolled kidney, liver, blood, gastrointestinal, endocrine, lung, heart, neurological, psychiatric, or brain disease, or with a history of gastrointestinal bleeding that is associated with a significant risk of bleeding or coagulopathy, or is clinically significant (such as requiring hospitalization or blood transfusion), or with other chronic medical conditions that are not eligible for participation in this clinical trial, or having a history of malignancy, other than non-metastatic basal cell carcinoma or skin squamous cell carcinoma or carcinoma in situ of the cervix with appropriate treatment and no signs of recurrence;
• Clinically important laboratory test indicators are abnormal, including: abnormal blood routine: hemoglobin (Hb) \< 100g/L, or white blood cell count (WBC) \< 3.5×10\^9/L; Abnormal liver function: aspartate aminotransferase (AST) ≥1.5×ULN, or alanyl aminotransferase (ALT) ≥1.5×ULN, or total bilirubin (TBIL) ≥1.5×ULN; Abnormal renal function: creatinine (Cr) ≥1×ULN; any other laboratory test indicators that researchers think may affect the evaluation of test results;
• Active and uncontrolled viral and bacterial infections at the time of screening, such as human immunodeficiency virus(HIV), hepatitis B virus(HBV), hepatitis C virus (HCV), syphilis, tuberculosis test results, or if there are any clinical symptoms of bacterial, viral, parasitic or fungal infection requiring treatment;
• Pregnant or breastfeeding women; having pregnancy plans during the clinical trial and within 1 month after the last dose, and do not want to take medically accepted reliable contraceptive methods;
• History of allergy to any investigational therapeutic drug or its excipients;
• History or evidence of alcohol or drug abuse within the six months prior to randomization;
• Use of other immunosuppressive drugs, including but not limited to hydroxychloroquine, methotrexate, cyclosporin A, cyclophosphamide, tacrolimus, mycophenolate, tripterygium, and compound glycyrrhizin, within 30 days or 5 half-lives (whichever is older) prior to screening;
• The investigator determines that the subjects have any conditions that make them unfit to participate in the experiment (such as weak health, poor compliance, etc.).

Sponsors & Collaborators

• Hubei Biological Medicine Industrial Technology Institute Co., Ltd.: lead

Study Sites (1)

West China Hospital,Sichuan University

Chengdu, Sichuan, China

RECRUITING

MeSH Terms

Conditions

Chronic Urticaria

Condition Hierarchy (Ancestors)

Urticaria; Skin Diseases, Vascular; Skin Diseases; Skin and Connective Tissue Diseases; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Jie ZHU

CONTACT

+86 027 87055350; zhujie@renfu.com.cn

Yaojun XUE

CONTACT

+86 027 87055350; xueyaojun@renfu.com.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 28, 2024
• First Posted: March 6, 2024
• Study Start: December 13, 2023
• Primary Completion: December 1, 2025
• Study Completion: January 1, 2026
• Last Updated: March 7, 2024

Record last verified: 2024-02

Locations

CN (1)